MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1136/jnnp-2023-332443

Медицинская библиотека · Journal of neurology, neurosurgery, and psychiatry · 2024

Excellent response to anti-CD38 therapy with daratumumab in a patient with severe refractory CANOMAD.

Pascual-Goñi Elba, Collet Roger, Tejada-Illa Clara, Martín-Aguilar Lorena, Caballero-Ávila Marta, Lleixà Cinta, Novelli Silvana, López-Pardo Jordi, Sanfeliu Albert Esquirol, Mariscal Anais, Álvaro Gargallo Yolanda, Martínez-Hernández Eugenia, Cocho Dolores, Querol Luis

Клинический случайСтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

BACKGROUND

Intravenous immunoglobulin (IVIG) and rituximab are considered the first-line and second-line treatments for Chronic Ataxic Neuropathy and Ophthalmoplegia with IgM-paraprotein, cold Agglutinins, and anti-Disialosyl antibodies (CANOMAD), with an overall clinical response around 50%. New anti-CD38 daratumumab, targeting long-lived plasma cells, has been reported as a promising therapy for treatment-refractory antibody-mediated disorders. We report the first case of a severe refractory CANOMAD, successfully treated with daratumumab.

METHODS

A patient in their 70s with severe relapsing CANOMAD, refractory to IVIG, steroids, rituximab and ibrutinib developed severe tetraparesis and respiratory failure. Plasma exchange (PE) improved motor and ventilatory function; however, after 6 weeks, patient remained PE dependent. Intravenous daratumumab was initiated at 16 mg/kg weekly for 3 weeks, every 2 weeks for the second and third month, and monthly afterwards.

RESULTS

After 3 weeks of starting daratumumab, PE was discontinued and, since then, the patient evolved to complete recovery. Antidisialosyl antibody titres decreased after PE and remained stable during daratumumab. Serum neurofilament light-chain levels were elevated in the exacerbation phase and normalised after daratumumab. The patient remains in clinical remission under monthly daratumumab, 12 months after initiation.

CONCLUSIONS

The first patient with aggressive treatment-refractory CANOMAD treated with daratumumab provides proof-of-principle evidence that daratumumab may be an effective treatment in IgM-related neuropathies.

Для цитирования: Pascual-Goñi Elba, Collet Roger, Tejada-Illa Clara, Martín-Aguilar Lorena, Caballero-Ávila Marta, Lleixà Cinta, Novelli Silvana, López-Pardo Jordi, Sanfeliu Albert Esquirol, Mariscal Anais, Álvaro Gargallo Yolanda, Martínez-Hernández Eugenia, Cocho Dolores, Querol Luis. Excellent response to anti-CD38 therapy with daratumumab in a patient with severe refractory CANOMAD.. Journal of neurology, neurosurgery, and psychiatry. 2024. DOI: 10.1136/jnnp-2023-332443.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.